GlassScriptPhysician profile
Gary M Cohen
NPI 1710979224
$14,441.59
in general payments reported to CMS, 2019-2025
63 companies · $2,632 in 2025
The $2,632 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $1,774 · 2021: $2,462 · 2022: $1,953 · 2023: $1,938 · 2024: $2,017 · 2025: $2,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,587.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.43 | 2019-2025 | Vraylar, Linzess, Ubrelvy |
| Lilly USA, LLC | $1,344.47 | 2019-2025 | Jardiance, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $1,135.38 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $1,059.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $811.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.08 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novo Nordisk INC | $534.88 | 2019-2025 | Wegovy, Ozempic |
| Collegium Pharmaceutical, INC. | $522.25 | 2019-2025 | Xtampza, Belbuca |
| Kowa Pharmaceuticals America, INC. | $496.76 | 2019-2023 | Seglentis, Livalo |
| Astrazeneca Pharmaceuticals LP | $454.22 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $391.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Axsome Therapeutics, INC. | $329.55 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $293.49 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $275.01 | 2022-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $269.02 | 2019-2023 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.